$SRPT
Análise IAGerado em May 11, 2026
AI Score
Hold$SRPT
Sarepta Therapeutics
$SRPTNASDAQHealthcareMid-Cap
Sarepta develops RNA-based therapeutics for rare neuromuscular diseases including Duchenne muscular dystrophy.
Market Cap
$12.0B
Revenue (TTM)
$1.5B
+35.0%
Net Income (TTM)
-$0.5B
N/A
EPS (TTM)
-$5.50
P/E Ratio
N/A
Dividend Yield
0.0%
52-Week Range
$85-$170
Beta
1.12
Dimension Scores
Fundamental
45Technical
52Sentiment
62Risk / Reward
48Momentum
65Financial Health
Profitability
50weak
Growth
68moderate
Liquidity
56strong
Solvency
47moderate
Efficiency
43moderate
Valuation, technical analysis, investment thesis, risk assessment and more for $SRPT
Free · No credit card required
Aviso: Análise gerada por IA apenas para fins educacionais. Não constitui aconselhamento financeiro. Sempre consulte um consultor financeiro qualificado.